A new liquid treatment for tumors with rich blood supply
Official title: Water-based liquid embolic agent for the treatment of vascular rich tumors
Funded at Aquatex Medical, INC. · NIH-10766633 · Data updated 2026-11-12
This study is testing a new liquid treatment called the Aqua Embolic System to help block blood flow to certain tumors, making it a better option for patients with specific types of cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aquatex Medical, INC. NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | July 5, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $399,528 |
| NIH project number | 1R41CA277860-01A1 |
| Project ID | NIH-10766633 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with hypervascular tumors that require embolization treatment.
✕Less likely to help
Patients with non-hypervascular tumors or those who are not candidates for embolization procedures may not benefit from this research.
What this research studies
This research focuses on developing a novel liquid embolic material called the Aqua Embolic System (AES) to enhance the treatment of hypervascular tumors. The AES is designed to be injected through a catheter into the blood vessels feeding the tumor, effectively blocking blood flow and causing tumor cell death. This method aims to overcome the limitations of current embolic materials, such as poor tissue penetration and incomplete vessel occlusion. By improving the efficacy and safety of trans-arterial embolization (TAE), this research could provide a more effective treatment option for patients with certain types of cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with hypervascular tumors.
How similar studies have gone: While liquid embolic materials have been explored, this specific approach is novel and has not yet been tested in the context of hypervascular tumors.
Where this research is happening
-
Aquatex Medical, INC.
Irvine, United States Active
Researchers
- Principal investigator: Yuki, Ichiro — Aquatex Medical, INC.
- Study coordinator: Yuki, Ichiro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.